The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study

Paolo Bosco, Alberto Redolfi, Martina Bocchetta, Clarissa Ferrari, Anna Mega, Samantha Galluzzi, Mark Austin, Andrea Chincarini, D. Louis Collins, Simon Duchesne, Bénédicte Maréchal, Alexis Roche, Francesco Sensi, Robin Wolz, Montserrat Alegret, Frederic Assal, Mircea Balasa, Christine Bastin, Anastasia Bougea, Derya Durusu Emek-SavaşSebastiaan Engelborghs, Timo Grimmer, Galina Grosu, Milica G. Kramberger, Brian Lawlor, Gorana Mandic Stojmenovic, Mihaela Marinescu, Patrizia Mecocci, José Luis Molinuevo, Ricardo Morais, Ellis Niemantsverdriet, Flavio Nobili, Konstantinos Ntovas, Sarah O'Dwyer, George P. Paraskevas, Luca Pelini, Agnese Picco, Eric Salmon, Isabel Santana, Oscar Sotolongo-Grau, Luiza Spiru, Elka Stefanova, Katarina Surlan Popovic, Magda Tsolaki, Görsev G. Yener, Dina Zekry, Giovanni B. Frisoni

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction Hippocampal volume is a core biomarker of Alzheimer's disease (AD). However, its contribution over the standard diagnostic workup is unclear. Methods Three hundred fifty-six patients, under clinical evaluation for cognitive impairment, with suspected AD and Mini–Mental State Examination ≥20, were recruited across 17 European memory clinics. After the traditional diagnostic workup, diagnostic confidence of AD pathology (DCAD) was estimated by the physicians in charge. The latter were provided with the results of automated hippocampal volumetry in standardized format and DCAD was reassessed. Results An increment of one interquartile range in hippocampal volume was associated with a mean change of DCAD of −8.0% (95% credible interval: [−11.5, −5.0]). Automated hippocampal volumetry showed a statistically significant impact on DCAD beyond the contributions of neuropsychology, 18F-fluorodeoxyglucose positron emission tomography/single-photon emission computed tomography, and cerebrospinal fluid markers (−8.5, CrI: [−11.5, −5.6]; −14.1, CrI: [−19.3, −8.8]; −10.6, CrI: [−14.6, −6.1], respectively). Discussion There is a measurable effect of hippocampal volume on DCAD even when used on top of the traditional diagnostic workup.

Original languageEnglish
Pages (from-to)1013-1023
Number of pages11
JournalAlzheimer's and Dementia
Volume13
Issue number9
DOIs
Publication statusPublished - Sep 1 2017

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Diagnostic confidence of AD
  • Hippocampal volume
  • Medial temporal lobe atrophy

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study'. Together they form a unique fingerprint.

Cite this